Literature DB >> 15383742

[18F]FDG-PET in patients with Alzheimer's disease: marker of disease spread.

D Bittner1, G Grön, H Schirrmeister, S N Reske, M W Riepe.   

Abstract

BACKGROUND: It is not known yet whether temporoparietal glucose hypometabolism in patients with probable Alzheimer's disease (AD) reflects disease severity or different subtypes of patients.
METHODS: Twenty-five subjects with mild probable AD [NINCDS-ADRDA criteria; age 65.8 +/- 9.3 years (mean +/- SD); Mini-Mental State Examination (MMSE) 26.0 +/- 3.3] were investigated. [(18)F]FDG-PET data were analyzed visually with raters blinded to the diagnosis and with a quantitative analysis in the region of interest on individual anatomically normalized PET scans.
RESULTS: Thirteen of 25 patients showed temporoparietal hypometabolism on visual inspection (PET+; age 65.7 +/- 10.7), 12 patients had normal FDG-PET results (PET-; age 65.9 +/- 8.0; n.s.). The MMSE and immediate reproduction of the Wechsler Memory Scale (WMS-R-I) were 27.7 +/- 1.9 and 31.1 +/- 6.1 in the PET- vs. 24.5 +/- 3.6 (p = 0.012) and 22.0 +/- 7.4 (p = 0.006) in the PET+ group. Immediate and delayed recall in the California Verbal Learning Test and delayed reproduction in the Wechsler Memory Scale were alike. Regression analysis revealed a significant correlation of temporoparietal glucose metabolism with the block span (r = 0.60; p < 0.01) and the WMS-R-I (r = 0.68; p < 0.01) but not with measures of hippocampal function.
CONCLUSIONS: Temporoparietal glucose metabolism in patients with very mild AD is a sign of disease spread beyond the temporal lobe. This may aid in establishing objective parameters for future therapeutic studies. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383742     DOI: 10.1159/000080967

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  4 in total

1.  Multi-modal imaging predicts memory performance in normal aging and cognitive decline.

Authors:  K B Walhovd; A M Fjell; A M Dale; L K McEvoy; J Brewer; D S Karow; D P Salmon; C Fennema-Notestine
Journal:  Neurobiol Aging       Date:  2008-10-05       Impact factor: 4.673

2.  Additive scales in degenerative disease--calculation of effect sizes and clinical judgment.

Authors:  Matthias W Riepe; David Wilkinson; Hans Förstl; Andreas Brieden
Journal:  BMC Med Res Methodol       Date:  2011-12-16       Impact factor: 4.615

3.  Drug-induced cerebral glucose metabolism resembling Alzheimer's Disease: a case study.

Authors:  Matthias W Riepe; Britta Walther; Catharina Vonend; Ambros J Beer
Journal:  BMC Psychiatry       Date:  2015-07-11       Impact factor: 3.630

4.  Study of the Influence of Age in 18F-FDG PET Images Using a Data-Driven Approach and Its Evaluation in Alzheimer's Disease.

Authors:  Jiehui Jiang; Yiwu Sun; Hucheng Zhou; Shaoping Li; Zhemin Huang; Ping Wu; Kuangyu Shi; Chuantao Zuo; Alzheimer's Disease Neuroimaging Initiative
Journal:  Contrast Media Mol Imaging       Date:  2018-02-08       Impact factor: 3.161

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.